

Report from Finance & Business Development Committee following its meeting of 31st January 2018

Decisions / approvals made (within delegated authority)

The Committee received reports on

- the draft 3 year operational and business plan was discussed and minor changes to be made re clarity of recommendations for Board approval in February 2018.
- the CIP savings plan for 2018/19
- discussions from the Finance, Infrastructure and Operational Delivery sub -committees
- the proposed new approach to performance reporting
- the impact of Carillion on the new build in Liverpool

Assurances provided to the Trust Board (excluding Strategic Plan Actions / BAF)

See below

Trust Board Business Plan 2017/18 Actions (Progress updates)

Transforming How Cancer Care is Provided Across the Network	<p>An update presentation was received on the new build and potential implications re Carillion and related dependencies .</p> <p>An update was also received on delays to Laing O Rourke's filing their Accounts. The Committee was updated that the Trust is arranging to meet with Laings Group FD</p> <p>A further presentation will be made to the Board.</p>
Continuous Improvement and Innovation	<p>An update on bed occupancy was received. An update was provided on business cases relating to Interventional Radiology which is currently work in progress..</p>
Financial sustainability	<p>The Trust is reporting a surplus of £2,856k against a plan of £2,746k. CIP savings of £1,450k have been achieved, £83K above plan. Financial risk rating is 1.</p> <p>Clinical activity for Haemato-Oncology was above plan by £321k.</p> <p>Capital expenditure was £13,290k against a plan of £31,497k. Agency spend was well within the NHSI cap (actual spend £534k against £916k cap)</p>
Generating Intelligence	

Delegated Actions from Board
None

Areas of non- delivery
None

New / mitigated risks

The impact Carillion will have on the Trust was discussed. A formal risk assessment of Haemato-Oncology will take place pending their delayed move into the Royal.

.

Key items for Board consideration

Initial impact on the Trust from the Carillion situation

Impact on Haemato-Oncology if the move to the Royal is delayed by 12 months

Recommendation

Trust Board to note the report and detail any requests for further scrutiny or assurance.